PATENT CLAIM ANALYSIS

Application Number: 16091701
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-04
Patent Classification: ["514", "422000"]

Abstract:
Prodigiosin analogs which reactivate the p53 pathway are provided, as well as compositions of these compounds, and methods for reactivation of the p53 pathway using these compounds are provided. The prodigiosin analogs may be used to treat cancer in which p53 mutation plays a role, including prostate cancer, breast cancer, kidney cancer, ovarian cancer, lymphoma, leukemia, and glioblastoma, among others.

Claim (Index 17):
The composition of  claim 5 , wherein the composition is a solid dosage form.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 97.0
- Lexical Diversity: 1.6
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15514623', '14764236', '12866133', '14261175', '15074027']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7140234335454981
- 35 USC 102 Novelty (BERT): 0.5309592239889308
- Combined Prediction Score: 0.6957170125898414
- Mean Citation Score: 207.50458
- Max Citation Score: 243.87157
- Similarity Product: 120.58625952268778

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test